Market closed
UCB/€UCB
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About UCB
UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.
Ticker
€UCB
Sector
Trading on
BSE
Industry
Pharmaceuticals
Headquarters
Employees
9,215
Website
UCB Metrics
BasicAdvanced
€32B
29.64
€5.61
0.34
€0.95
0.57%
Price and volume
Market cap
€32B
Beta
0.34
52-week high
€198.95
52-week low
€112.65
Average daily volume
307K
Dividend rate
€0.95
Financial strength
Current ratio
1.357
Quick ratio
0.871
Long term debt to equity
29.544
Total debt to equity
30.172
Dividend payout ratio (TTM)
24.32%
Interest coverage (TTM)
5.19%
Management effectiveness
Return on assets (TTM)
3.18%
Return on equity (TTM)
11.21%
Valuation
Price to earnings (TTM)
29.642
Price to revenue (TTM)
5.131
Price to book
3.15
Price to tangible book (TTM)
65.1
Price to free cash flow (TTM)
34.311
Dividend yield (TTM)
0.57%
Forward dividend yield
0.57%
Growth
Revenue change (TTM)
18.72%
Earnings per share change (TTM)
218.48%
3-year revenue growth (CAGR)
2.12%
3-year earnings per share growth (CAGR)
0.91%
3-year dividend per share growth (CAGR)
2.26%
What the Analysts think about UCB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for UCB stock.
UCB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
UCB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe
FAQs
What’s the current market cap for UCB stock?
UCB (UCB) has a market cap of €32B as of March 29, 2025.
What is the P/E ratio for UCB stock?
The price to earnings (P/E) ratio for UCB (UCB) stock is 29.64 as of March 29, 2025.
Does UCB stock pay dividends?
Yes, the UCB (UCB) stock pays dividends to shareholders. As of March 29, 2025, the dividend rate is €0.952 and the yield is 0.57%. UCB has a payout ratio of 24.32% on a trailing twelve-month basis.
When is the next UCB dividend payment date?
The next UCB (UCB) dividend payment date is unconfirmed.
What is the beta indicator for UCB?
UCB (UCB) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
